Prednisone: Drug information
Copyright 1978-2018 Lexicomp, Inc. All rights reserved.
(For additional information see "Prednisone: Patient drug information" and see "Prednisone: Pediatric drug information")

For abbreviations and symbols that may be used in Lexicomp (show table)
Brand Names: US
  • Deltasone;
  • PredniSONE Intensol;
  • Rayos
Brand Names: Canada
  • Apo-Prednisone;
  • JAA-Prednisone;
  • Teva-Prednisone;
  • Winpred
Pharmacologic Category
  • Corticosteroid, Systemic
Dosing: Adult

General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Oral: Initial: 5 to 60 mg daily:

Note: Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.

Prednisone taper (other regimens also available):

Day 1: 30 mg divided as 10 mg before breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime

Day 2: 5 mg at breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime

Day 3: 5 mg 4 times daily (with meals and at bedtime)

Day 4: 5 mg 3 times daily (breakfast, lunch, bedtime)

Day 5: 5 mg 2 times daily (breakfast, bedtime)

Day 6: 5 mg before breakfast

Indication-specific dosing:

Acute asthma (off-label dose): Oral: 40 to 60 mg/day for 3 to 10 days; administer as single or 2 divided doses (NAEPP 2007).

Acute exacerbations of chronic obstructive pulmonary disease (COPD) (off-label use for immediate release products; off-label dose): Oral: 40 mg once daily for 5 days (GOLD 2014).

Anaphylaxis, adjunctive treatment (off-label dose): Oral: 0.5 mg/kg (Lieberman 2005)

Antineoplastic: Oral: Usual range: 10 mg daily to 100 mg/m2/day (depending on indication). Refer to specific protocol for dosing and administration details.

Autoimmune hepatitis (off-label use): Oral: Initial: 60 mg daily for 1 week, followed by 40 mg daily for 1 week, then 30 mg daily for 2 weeks, then 20 mg daily. Half this dose should be given when used in combination with azathioprine (AASLD [Manns 2010]).

Bell palsy (off-label use): Oral: 60 mg daily for 5 days, followed by a 5-day taper. Treatment should begin within 72 hours of onset of symptoms (OHNS [Baugh 2013]).

Crohn disease, moderate/severe (off-label dose): Oral: 40 to 60 mg daily until resolution of symptoms and resumption of weight gain (usual duration: 7 to 28 days) (Lichtenstein 2009).

Dermatomyositis/polymyositis (off-label dose): Oral: 1 mg/kg daily (range: 0.5 to 1.5 mg/kg/day), often in conjunction with steroid-sparing therapies; depending on response/tolerance, consider slow tapering after 2 to 8 weeks depending on response; taper regimens vary widely, but often involve 5 to 10 mg decrements per week and may require 6 to 12 months to reach a low once-daily or every-other-day dose to prevent disease flare (Briemberg 2003; Hengstman 2009; Iorizzo 2008; Wiendl 2008).

Duchenne muscular dystrophy (off-label use): Oral: 0.75 mg/kg/day or 10 mg/kg/weekend, divided over 2 days. When used daily, the dose may be decreased to 0.3 mg/kg/day in patients who experience adverse reactions. Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses above 0.75 mg/kg/day provide greater efficacy (AAN [Gloss 2016]; Escolar 2011; Matthews 2016).

Giant cell arteritis (off-label use): Oral: Initial: 40 to 60 mg daily; typically requires 1 to 2 years of treatment, but may begin to taper after 2 to 3 months; alternative dosing of 30 to 40 mg daily has demonstrated similar efficacy (Hiratzka 2010).

Glucocorticoid remediable aldosteronism, treatment (off-label use): Oral: Initial: 2.5 to 5 mg once daily preferably at bedtime to suppress early morning ACTH surge (Funder 2016)

Gout, treatment of acute flare (off-label): Oral: Initial: ≥0.5 mg/kg for 5 to 10 days (ACR guidelines [Khanna 2012]) or 30 to 35 mg daily for 3 to 5 days (EULAR [Richette 2017])

Graves orbitopathy (off-label use): Oral: 0.4 to 0.5 mg/kg/day, starting 1 to 3 days after radioactive iodine treatment, and continued for 1 month, then gradually taper over 2 months (Ross 2016).

Herpes zoster (off-label use): Oral: 60 mg daily for 7 days, followed by 30 mg daily for 7 days, then 15 mg daily for 7 days (Dworkin 2007).

Immune thrombocytopenia (off-label dose): Oral: 1 to 2 mg/kg/day (American Society of Hematology 1997).

Immune thrombocytopenia in pregnancy: Initial: 10 to 20 mg/day (ACOG 2016). Adjust to the minimum effective dose to achieve response; generally continue for at least 21 days, then taper to the minimum effective dose required to maintain platelet count (ACOG 2016; Neunert 2011).

Lupus nephritis, induction (off-label dose): Oral:

Class III-IV lupus nephritis: 0.5 to 1 mg/kg/day (after glucocorticoid pulse) tapered after a few weeks to lowest effective dose, in combination with an immunosuppressive agent (Hahn 2012).

Class V lupus nephritis: 0.5 mg/kg/day for 6 months in combination mycophenolate mofetil; if not improved after 6 months, use 0.5 to 1 mg/kg/day (after a glucocorticoid pulse) for an additional 6 months in combination with cyclophosphamide (Hahn 2012).

Multiple sclerosis, acute exacerbations:

Note: Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (AAN [Scott 2011]; NICE 2014).

Oral: 200 mg daily for 1 week, followed by 80 mg every other day for 1 month.

Pericarditis (off-label use):

Recurrent pericarditis : Oral: 1 to 1.5 mg/kg once daily for at least 1 month; taper dose over a 3-month period (Maisch 2004)

Tuberculosis pericarditis : Oral: 1 to 2 mg/kg once daily for 5 to 7 days followed by 6 to 8 weeks of tapering (Maisch 2004) or 60 mg once daily for 4 weeks, followed by 30 mg once daily for 4 weeks, 15 mg once daily for 2 weeks, and 5 mg once daily for 1 week (Reuter 2006).

Pneumocystis pneumonia (adjunctive therapy) in HIV-infected patients (off-label dose): Oral: 40 mg twice daily for 5 days beginning as early as possible and within 72 hours of PCP therapy, followed by 40 mg once daily on days 6 through 10, followed by 20 mg once daily on days 11 through 21 (DHHS [adult] 2015).

Polymyalgia rheumatica (off-label dose): Oral: Evidence to support an optimal dose and duration are lacking; recommendations provided are general guidelines only. Individualize therapy using the minimum effective dose and duration (Dejaco [EULAR/ACR 2015]):

Initial: Dosage range: 12.5 to 25 mg daily; consider higher doses within this range for patients at high risk of relapse and low risk of adverse events; consider lower doses within this range for patients with high risk factors for side effects (eg, diabetes, osteoporosis, glaucoma). Single daily doses are preferred over divided daily doses. Avoid initial doses ≤7.5 mg/day or >30 mg/day.

Tapering: For initial dosing, taper to a dose of 10 mg/day within 4 to 8 weeks. If relapse occurs, increase dosing to the prerelapse dose and gradually taper back to the dose which relapse occurred within 4 to 8 weeks. Once remission is achieved (initial or relapse therapy), taper daily dose by 1 mg every 4 weeks (or by 1.25 mg decrements if using schedules such as 10 mg and 7.5 mg on alternate days) until discontinuation.

Prostate cancer, metastatic (off-label use): Oral: 5 mg twice daily (in combination with abiraterone) until disease progression or unacceptable toxicity (de Bono 2011; Ryan 2015) or 10 mg once daily (in combination with cabazitaxel) for up to 10 cycles (de Bono 2010) or 5 mg twice daily (in combination with docetaxel) for up to 10 cycles (Berthold 2008; Tannock 2004).

Rheumatoid arthritis (off-label dose): Oral: ≤10 mg daily (American College of Rheumatology 2002).

Subacute thyroiditis (off-label use): Oral: Initial: 40 mg/day for 1 to 2 weeks; gradually taper over 2 to 4 weeks or longer depending on clinical response (Ross 2016).

Takayasu arteritis (off-label use): Oral: Initial: 40 to 60 mg daily; taper to lowest effective dose when ESR and CRP levels are normal; usual duration: 1 to 2 years (Hiratzka 2010).

Thyrotoxicosis, type 2 amiodarone-induced (off-label use): Oral: 40 mg once daily for 14 to 28 days; gradually taper over 2 to 3 months depending on clinical response. Note: Use in combination with an antithyroid agent if etiology of thyrotoxicosis (eg type 1 or type 2) cannot be unequivocally determined or if patient is too clinically unstable to allow a trial of monotherapy (Ross 2016).

Tuberculosis, severe, paradoxical reactions (off-label dose): Oral: 1 mg/kg/day, gradually reduce after 1 to 2 weeks (AIDSinfo guidelines 2008).

Dosing: Pediatric

(For additional information see "Prednisone: Pediatric drug information")

General dosing; anti-inflammatory/immunosuppressive/endocrine disorders: Children and Adolescents: Oral: Refer to adult dosing.

Note: Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on severity of the disease and response of the patient rather than on strict adherence to dosage indicated by age, weight, or body surface area. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.

Indication-specific dosing:

Acute asthma (off-label dose): Oral:

Infants and Children <12 years: 1 to 2 mg/kg/day for 3 to 10 days (maximum: 60 mg/day) (NAEPP 2007).

Children ≥12 years and Adolescents: Refer to adult dosing.

Antineoplastic: Children and Adolescents: Oral: Refer to adult dosing or to specific protocol.

Autoimmune hepatitis (monotherapy or in combination with azathioprine) (off-label use): Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day for 2 weeks (maximum: 60 mg/day), followed by a taper over 6 to 8 weeks to a dose of 0.1 to 0.2 mg/kg/day or 2.5 to 5 mg daily (AASLD [Manns 2010]; Della Corte 2012).

Bell palsy (off-label use):

Infants, Children, and Adolescents <16 years: Oral: 1 mg/kg/day for 1 week, then taper over 1 week; ideally start within the 72 hours of onset of symptoms; maximum daily dose: 60 mg/day

Adolescents ≥16 years: Oral: Refer to adult dosing.

Duchenne muscular dystrophy (off-label use): Children ≥ 4 years and Adolescents: Oral: 0.75 mg/kg/day or 10 mg/kg/weekend, divided over 2 days. The dose may be decreased to 0.3 mg/kg/day in patients who experience adverse reactions. Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses above 0.75 mg/kg/day provide greater efficacy (AAN [Gloss 2016]; Escolar 2011; Matthews 2016).

Nephrotic syndrome; steroid sensitive (SSNS) (off-label dose): Children and Adolescents: Oral:

Initial episode: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, maximum dose: 40 mg/dose (Gipson 2009; KDIGO 2012; KDOQI 2013); duration of therapy based on patient response.

Relapse: 2 mg/kg/day or 60 mg/m2/day once daily, maximum daily dose: 60 mg/day, continue until complete remission for at least 3 days; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m2/dose on alternate days as a single dose, maximum dose: 40 mg/dose, recommended duration of alternate day dosing is variable: may continue for at least 4 weeks then taper. Longer duration of treatment may be necessary in patients who relapse frequently, some patients may require up to 3 months of treatment (Gipson 2009; KDIGO 2012; KDOQI 2013).

Maintenance therapy for frequently relapsing SSNS: Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/day on alternating days; other patients may require doses up to 0.7 mg/kg/dose every other day (KDIGO 2012; KDOQI 2013).

Pneumocystis pneumonia (adjunctive therapy) in HIV-infected patients (off-label dose): Oral:

Infants and Children: 1 mg/kg twice daily on days 1 to 5, followed by 0.5 to 1 mg/kg twice daily on days 6 to 10, followed by 0.5 mg/kg once daily on days 11 through 21 (DHHS [pediatric] 2013).

Adolescents: Refer to adult dosing.

Dosing: Geriatric

Refer to adult dosing; use the lowest effective dose.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer’s labeling.

Hemodialysis: Supplemental dose is not necessary.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer's labeling.

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Concentrate, Oral:

PredniSONE Intensol: 5 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]

Solution, Oral:

Generic: 5 mg/5 mL (5 mL [DSC], 120 mL, 500 mL)

Tablet, Oral:

Deltasone: 20 mg [scored; contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake]

Generic: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg, 10 mg, 5 mg

Tablet Delayed Release, Oral:

Rayos: 1 mg, 2 mg, 5 mg

Tablet Therapy Pack, Oral:

Generic: 10 mg (21 ea, 48 ea); 5 mg (21 ea, 48 ea)

Generic Equivalent Available (US)

May be product dependent

Administration

Administer after meals or with food or milk to decrease GI upset. May administer antacids between meals to help prevent peptic ulcers.

Delayed-release tablets: Swallow whole; do not break, divide, crush, or chew.

Oral solution, concentrate: Administer only with provided calibrated dropper.

Use

Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in drug hypersensitivity reactions, seasonal or perennial allergic rhinitis; serum sickness.

Dermatologic diseases: Atopic dermatitis; bullous dermatitis herpetiformis; contact dermatitis; exfoliative dermatitis/erythroderma; mycosis fungoides; pemphigus; severe erythema multiforme (Stevens-Johnson syndrome).

Immediate-release only: Severe psoriasis, severe seborrheic dermatitis.

Endocrine disorders: Congenital adrenal hyperplasia; hypercalcemia of malignancy; nonsuppurative thyroiditis; primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable.

GI diseases: During acute episodes in regional enteritis (Crohn disease) and ulcerative colitis.

Hematologic disorders: Acquired (autoimmune) hemolytic anemia; congenital (erythroid) hypoplastic anemia/Diamond-Blackfan anemia; immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) in adults; secondary thrombocytopenia in adults.

Delayed-release only: Pure red cell aplasia.

Immediate-release only: Erythroblastopenia (red blood cell anemia).

Neoplastic diseases:

Delayed-release only: Treatment of acute leukemia and aggressive lymphomas.

Immediate-release only: Palliative management of leukemias and lymphomas in adults; acute leukemia of childhood.

Nervous system (delayed-release only): Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Note: Treatment guidelines recommend the use of high dose IV or oral methylprednisolone for acute exacerbations of multiple sclerosis (Scott 2011; NICE 2014).

Ophthalmic diseases:

Delayed-release only: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as sympathetic ophthalmia; uveitis and ocular inflammatory conditions unresponsive to topical steroids.

Immediate-release only: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as allergic conjunctivitis, allergic corneal marginal ulcers, anterior segment inflammation, chorioretinitis, diffuse posterior uveitis and choroiditis, herpes zoster ophthalmicus, iridocyclitis, iritis, keratitis, optic neuritis, sympathetic ophthalmia.

Renal diseases: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that is caused by lupus erythematosus.

Respiratory diseases: Aspiration pneumonitis; asthma; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy; symptomatic sarcoidosis.

Delayed-release only: Acute exacerbations of chronic obstructive pulmonary disease (COPD); allergic bronchopulmonary aspergillosis; hypersensitivity pneumonitis; idiopathic bronchiolitis obliterans with organizing pneumonia; idiopathic eosinophilic pneumonias; idiopathic pulmonary fibrosis; Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV-positive individual who is also under treatment with appropriate anti-PCP antibiotics.

Immediate-release only: Berylliosis; Loeffler syndrome not manageable by other means.

Rheumatic disorders:

Maintenance therapy:

Delayed-release only: During an exacerbation or as maintenance therapy in selected cases of ankylosing spondylitis, dermatomyositis/polymyositis, polymyalgia rheumatica, psoriatic arthritis, relapsing polychondritis, rheumatoid arthritis including juvenile rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, vasculitis.

Immediate-release only: During an exacerbation or as maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus.

Short-term therapy:

Delayed release only: As adjunctive therapy for short-term administration in acute gouty arthritis.

Immediate-release only: As adjunctive therapy for short-term administration in acute and subacute bursitis; acute gouty arthritis; acute nonspecific tenosynovitis; ankylosing spondylitis; epicondylitis; posttraumatic osteoarthritis; psoriatic arthritis; rheumatoid arthritis including juvenile rheumatoid arthritis; synovitis of osteoarthritis.

Miscellaneous: Trichinosis with neurologic or myocardial involvement; tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.

Delayed-release only: Acute or chronic solid organ rejection.

Use: Off-Label

Acute exacerbation of chronic obstructive pulmonary disease (COPD); Bell palsy; Duchenne muscular dystrophy; Glucocorticoid remediable aldosteronism, treatment; Graves orbitopathy; Pericarditis; Prostate cancer (metastatic); Thyroiditis, subacute; Thyrotoxicosis (type 2 amiodarone-induced); Autoimmune hepatitis; Adjunctive therapy for pain management in immunocompetent patients with herpes zoster; Takayasu arteritis; Giant cell arteritis

Medication Safety Issues
Sound-alike/look-alike issues:

PredniSONE may be confused with methylPREDNISolone, Pramosone, prazosin, prednisoLONE, PriLOSEC, primidone, promethazine

Adverse Reactions

Frequency not defined.

Cardiovascular: Cardiac failure (in susceptible patients), hypertension

Central nervous system: Emotional lability, headache, increased intracranial pressure (with papilledema), myasthenia, psychiatric disturbance (including euphoria, insomnia, mood swings, personality changes, severe depression), seizure, vertigo

Dermatologic: Diaphoresis, facial erythema, skin atrophy, urticaria

Endocrine & metabolic: Cushing’s syndrome, decreased serum potassium, diabetes mellitus, fluid retention, growth suppression (children), hypokalemic alkalosis, hypothyroidism (enhanced), menstrual disease, negative nitrogen balance (due to protein catabolism), sodium retention

Gastrointestinal: Abdominal distention, carbohydrate intolerance, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis

Hematologic & oncologic: Bruise, Kaposi’s sarcoma, petechia

Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST

Hypersensitivity: Anaphylaxis, hypersensitivity reaction

Infection: Infection

Neuromuscular & skeletal: Amyotrophy, aseptic necrosis of bones (femoral and humeral heads), osteoporosis, pathological fracture (long bones), rupture of tendon (particularly Achilles tendon), steroid myopathy, vertebral compression fracture

Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, subcapsular posterior cataract

Miscellaneous: Wound healing impairment

<1%, postmarketing, and/or case reports: Venous thrombosis (Johannesdottir 2013)

Contraindications

Hypersensitivity to prednisone or any component of the formulation; administration of live or live attenuated vaccines with immunosuppressive doses of prednisone; systemic fungal infections

Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving >20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections.

• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.

• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used to treat viral hepatitis or cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination and fatalities have occurred.

• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).

• Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.

• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression or frank psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with HF and/or hypertension; long-term use has been associated with electrolyte disturbances, fluid retention, and hypertension. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.

• Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.

• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific]) due to perforation risk.

• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.

• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; effects may be enhanced.

• Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.

• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.

• Osteoporosis: Use with caution in patients with or who are at risk for osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.

• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.

• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.

• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.

• Pediatric: May affect growth velocity; growth and development should be routinely monitored in pediatric patients.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).

Other warnings/precautions:

• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.

• Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

(For additional information: Launch drug interactions program)

Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy

Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination

Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. Risk C: Monitor therapy

Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. Risk C: Monitor therapy

Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects. Risk D: Consider therapy modification

Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment. Risk D: Consider therapy modification

Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel. Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity. Risk D: Consider therapy modification

BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral). Risk C: Monitor therapy

Boceprevir: May increase the serum concentration of PredniSONE. Risk C: Monitor therapy

Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). Risk C: Monitor therapy

Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Risk C: Monitor therapy

Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Risk C: Monitor therapy

Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy

CycloSPORINE (Systemic): May increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of PredniSONE. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of PredniSONE. Risk C: Monitor therapy

Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Risk C: Monitor therapy

Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment. Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation. Risk D: Consider therapy modification

Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Echinacea: May diminish the therapeutic effect of Immunosuppressants. Risk D: Consider therapy modification

Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic). Risk C: Monitor therapy

Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Risk D: Consider therapy modification

Fluconazole: May increase the serum concentration of PredniSONE. Risk C: Monitor therapy

Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. Risk D: Consider therapy modification

Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Risk D: Consider therapy modification

Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic). Risk C: Monitor therapy

Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. Risk X: Avoid combination

Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. Risk C: Monitor therapy

Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification

Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. Risk C: Monitor therapy

Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination

MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment. Risk X: Avoid combination

Mitotane: May decrease the serum concentration of Corticosteroids (Systemic). Risk D: Consider therapy modification

Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination

Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification

Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. Risk C: Monitor therapy

Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Risk D: Consider therapy modification

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Risk C: Monitor therapy

Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Risk C: Monitor therapy

Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. Risk C: Monitor therapy

Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Risk C: Monitor therapy

Ritonavir: May increase the serum concentration of PredniSONE. Risk C: Monitor therapy

Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Risk D: Consider therapy modification

Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor therapy

Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. Risk C: Monitor therapy

Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Risk C: Monitor therapy

Somatropin: May diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite. Risk D: Consider therapy modification

Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. Risk C: Monitor therapy

Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic). Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives. If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects. Risk D: Consider therapy modification

Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Risk C: Monitor therapy

Tesamorelin: May decrease serum concentrations of the active metabolite(s) of PredniSONE. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel. Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome). Risk D: Consider therapy modification

Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Risk D: Consider therapy modification

Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy

Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. Risk C: Monitor therapy

Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Risk D: Consider therapy modification

Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided. Risk D: Consider therapy modification

Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. Risk C: Monitor therapy

Pregnancy Risk Factor

C/D (product specific) (show table)

Pregnancy Implications

Adverse events have been observed with corticosteroids in animal reproduction studies. Prednisone and its metabolite, prednisolone, cross the human placenta. In the mother, prednisone is converted to the active metabolite prednisolone by the liver. Prior to reaching the fetus, prednisolone is converted by placental enzymes back to prednisone. As a result, the level of prednisone remaining in the maternal serum and reaching the fetus are similar; however, the amount of prednisolone reaching the fetus is ~8 to 10 times lower than the maternal serum concentration (healthy women at term) (Beitins 1972).

Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.

When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Götestam Skorpen 2016; Makol 2011; Østensen 2009).

For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006). Prednisone is preferred by some guidelines when an oral corticosteroid is needed because placental enzymes limit passage to the embryo (Murase 2014).

Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased risk of perinatal mortality, preeclampsia, preterm birth, and low birth weight infants. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids, including prednisone, should be used to control acute exacerbations or treat severe persistent asthma (ACOG 2008; GINA 2016; Namazy 2016).

Prednisone may be used to treat lupus nephritis in pregnant women who have active nephritis or substantial extrarenal disease activity (Hahn 2012). Prednisone is recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated immune thrombocytopenia (ACOG 2016). Prednisone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant women with PAI should be monitored at least once each trimester (Bornstein 2016).

The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or [email protected]

Breast-Feeding Considerations

Prednisone and its metabolite, prednisolone, are present in breast milk. Actual concentrations are dependent upon maternal dose (Berlin 1979; Katz 1975; Sagraves 1981). Peak concentrations of prednisone and prednisolone in breast milk occur ~2 hours after an oral maternal dose (Berlin 1979; Sagraves 1981); the half-life in breast milk is 1.9 hours (prednisone) and 4.2 hours (prednisolone) (Sagraves 1981).

In a study which included six mother-infant pairs, adverse events were not observed in nursing infants (maternal prednisone dose not provided) (Ito 1993).

The manufacturer notes that when used systemically, maternal use of corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production) and therefore, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. Corticosteroids are generally considered acceptable in breastfeeding women when used in usual doses (Götestam Skorpen 2016; WHO 2002); however, monitoring of the breastfeeding infant is recommended (WHO 2002). Prednisone is one of the oral corticosteroids preferred for use in breastfeeding women (Butler 2014). If there is concern about exposure to the infant, some guidelines recommend waiting 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfeeding infant (based on a study using prednisolone) (Bae 2012; Butler 2014; Götestam Skorpen 2016; Leachman 2006; Makol 2011; Ost 1985).

Dietary Considerations

May require increased dietary intake of pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus; may require decreased dietary intake of sodium and potassium supplementation

Monitoring Parameters

Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); Hgb, occult blood loss; chest x-ray (at regular intervals during prolonged therapy); IOP with therapy >6 weeks.

Mechanism of Action

Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses. Antitumor effects may be related to inhibition of glucose transport, phosphorylation, or induction of cell death in immature lymphocytes. Antiemetic effects are thought to occur due to blockade of cerebral innervation of the emetic center via inhibition of prostaglandin synthesis.

Pharmacodynamics/Kinetics

Absorption: 50% to 90% (may be altered in hepatic failure, chronic renal failure, inflammatory bowel disease, hyperthyroidism, and in the elderly) (Frey 1990)

Protein binding (concentration dependent): <50% (Frey 1990)

Metabolism: Hepatic to metabolite prednisolone (active)

Half-life elimination: 2 to 3 hours

Time to peak: Oral: Immediate-release tablet: 2 hours; Delayed-release tablet: 6 to 6.5 hours

Excretion: Urine (as conjugates)

Pricing: US

Concentrate (PredniSONE Intensol Oral)

5 mg/mL (30 mL): $156.00

Solution (PredniSONE Oral)

5 mg/5 mL (120 mL): $96.00

Tablet Therapy Pack (PredniSONE Oral)

5MG (21) (21): $16.88

5MG (48) (48): $27.90

10MG (21) (21): $29.14

10MG (48) (48): $41.40

Tablet, EC (Rayos Oral)

1 mg (30): $3,012.12

2 mg (30): $3,012.12

5 mg (30): $3,012.12

Tablets (Deltasone Oral)

20 mg (20): $120.00

Tablets (PredniSONE Oral)

1 mg (100): $25.31

2.5 mg (100): $16.54

5 mg (100): $22.61

10 mg (100): $24.28

20 mg (100): $25.90

50 mg (100): $40.70

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Alfacort (UY);
  • Apo-Prednisone (NZ);
  • Cortancyl (FR, LB);
  • Cortiol (PT);
  • Cortiprex (CL, PE, PY);
  • Cutason (DE);
  • Dacortin (CH, ES);
  • Decortin (DE, HR);
  • Decortisyl (IE);
  • Dehydrocortison (BG);
  • Delcortin (DK);
  • Deltacortene (IT);
  • Deltasone (HK);
  • Deltison (SE);
  • Ednapron (CR, DO, GT, HN, MX, NI, PA, SV);
  • Encorton (PL);
  • Hostacortin (ID);
  • Lexacort (ID);
  • Lodotra (AU, ES, GB, HU, IL, KR, LU, RO, SG, SK, TR);
  • Me-Korti (FI);
  • Meticorten (AR, BR, CL, CO, CR, DO, GT, HN, MX, NI, PA, PE, PT, SV, VE);
  • Metilpres (AR);
  • Nisona (PE);
  • Nizon (HR);
  • Norapred (MX);
  • Nurison (NL);
  • Orapred (PE);
  • Panafcort (AU, ZA, ZW);
  • Parmenison (AT);
  • Pehacort (ID);
  • Predicor (LB);
  • Prednicort (BE, LU, PY);
  • Prednidib (MX);
  • Predniment (NL);
  • Prednimut (NL);
  • Prednison (FI, NO);
  • Prednison Galepharm (CH);
  • Prednison Streuli (CH);
  • Prednison ”Dak” (DK);
  • Prednisone (CY);
  • Predone (QA, SA);
  • Predoral (PH);
  • Predsone (PH);
  • Presacor (EC);
  • Prolix 20 (PH);
  • Pulmison (ZA);
  • Qualisone (PH);
  • Rectodelt (HU);
  • Sone (AU);
  • Systocor (PH)
Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics. Technical report congenital adrenal hyperplasia. Pediatrics. 2000;106(6):1511-1518. [PubMed 11099616]
  3. American College of Obstetrics and Gynecology (ACOG), ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol. 2008;111(2 Pt 1):457-464. [PubMed 18238988]
  4. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in Pregnancy. Obstet Gynecol. 2016;128(3):e43-e53. doi: 10.1097/AOG.0000000000001641. [PubMed 27548554]
  5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, “Guidelines for the Management of Rheumatoid Arthritis: 2002 Update,” Arthritis Rheum, 2002, 46(2):328-46. [PubMed 11840435]
  6. Bae YS, Van Voorhees AS, Hsu S, et al, "Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation," J Am Acad Dermatol, 2012, 67(3):459-77. [PubMed 22018758]
  7. Bartalena L, Brogioni S, Grasso L, et al, “Treatment Of Amiodarone-Induced Thyrotoxicosis, A Difficult Challenge: Results Of A Prospective Study,” J Clin Endocrinol Metab, 1996, 81(8):2930-3. [PubMed 8768854]
  8. Basaria S and Cooper DS, “Amiodarone and the Thyroid,” Am J Med, 2005, 118(7):706-14. [PubMed 15989900]
  9. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-3448. [PubMed 25199761]
  10. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg. 2013;149(3 suppl):s1-s27. [PubMed 24189771]
  11. Beitins IZ, Bayard F, Ances IG, et al, “The Transplacental Passage of Prednisone and Prednisolone in Pregnancy Near Term,” J Pediatr, 1972, 81(5):936-45. [PubMed 5086721]
  12. Berlin Jr CM, Kaiser DG, Demers L. Excretion of prednisone and prednisolone in human milk. Pharmacologist. 1979;21:264.
  13. Berthold DR, Pond GR, Soban F, et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. J Clin Oncol. 2008;26(2):242-245. [PubMed 18182665]
  14. Bogazzi F, Bartalena L, Cosci C, et al, “Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study,” J Clin Endocrinol Metab, 2003, 88(5):1999-2002. [PubMed 12727944]
  15. Bogazzi F, Bartalena L, Tomisti L, et al, “Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting From Destructive Thyroiditis is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations,” J Clin Endocrinol Metab, 2007, 92(2):556-62. [PubMed 17148557]
  16. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23(9):1344-1347. [PubMed 10951436]
  17. Boot AM, Nauta J, Hokken-Koelega AC, et al, “Renal Transplantation and Osteoporosis,” Arch Dis Child, 1995, 72(6):502-6. [PubMed 7618934]
  18. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710. [PubMed 26760044]
  19. Bowman H and Lennard TW, “Immunosuppressive Drugs,” Br J Hosp Med, 1992, 48(9):570-3. [PubMed 1282440]
  20. Briemberg HR and Amato AA, “Dermatomyositis and Polymyositis,” Curr Treat Options Neurol, 2003, 5(5):349-56. [PubMed 12895397]
  21. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. [PubMed 24528912]
  22. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  23. Coursin DB and Wood KE, “Corticosteroid Supplementation for Adrenal Insufficiency,” JAMA, 2002, 287(2):236-40. [PubMed 11779267]
  24. Czaja AJ and Freese DK, “Diagnosis and Treatment of Autoimmune Hepatitis,” Hepatology, 2002, 36(2):479-97. [PubMed 12143059]
  25. de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med. 2011;364(21):1995-2005. [PubMed 21612468 ]
  26. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154. [PubMed 20888992]
  27. de Jonghe B, Sharshar T, Lefaucheur JP, et al, “Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,” JAMA, 2002, 288(22):2859-67. [PubMed 12472328]
  28. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-1807. doi: 10.1136/annrheumdis-2015-207492. [PubMed 26359488]
  29. Della Corte C, Sartorelli MR, Sindoni CD, et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. Eur J Gastroenterol Hepatol. 2012;24(7):739-746. [PubMed 22495399]
  30. Dellinger RP, Levy MM, Carlet JM, et al, “Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,” Intensive Care Med, 2008, 34(1):17-60. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf [PubMed 18058085]
  31. Deltasone (prednisone) [prescribing information]. Petaluma, CA: Oculus Innovative Sciences; Received on August 20, 2015.
  32. DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at http://aidsinfo.nih.gov
  33. “Diagnosis and Treatment of Idiopathic Thrombocytopenic Purpura: Recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel,” Ann Intern Med, 1997, 126(4):319-26. [PubMed 9036806]
  34. Dworkin RH, Johnson RW, Breuer J, et al, “Recommendations for the Management of Herpes Zoster,” Clin Infect Dis, 2007, 44(Suppl 1):1-26. [PubMed 17143845]
  35. Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77:444–452. doi: 10.1212/WNL.0b013e318227b164. [PubMed 21753160]
  36. Frey BM and Frey FJ, “Clinical Pharmacokinetics of Prednisone and Prednisolone,” Clin Pharmacokinet, 1990, 19(2):126-146. [PubMed 2199128]
  37. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
  38. Gambertoglio JG, Amend WJ Jr, and Benet LZ, “Pharmacokinetics and Bioavailability of Prednisone and Prednisolone in Healthy Volunteers and Patients: A Review,” J Pharmacokinet Biopharm, 1980, 8(1):1-52. [PubMed 6991663]
  39. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747-757. [PubMed 19651590]
  40. Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org. Updated 2016. Accessed June 8, 2016.
  41. Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) website. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf. Published January 2015. Accessed February 5, 2015.
  42. Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465-472. doi: 10.1212/WNL.0000000000002337. [PubMed 26833937]
  43. Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” J Natl Cancer Inst, 2002, 94(22):1712-8. [PubMed 12441327]
  44. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. [PubMed 26888948]
  45. Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” J Natl Cancer Inst, 2002, 94(22):1712-8. [PubMed 12441327]
  46. Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209-2213. [PubMed 23136264]
  47. Grotz WH, Mundinger FA, Gugel B, et al, “Bone Mineral Density After Kidney Transplantation: A Cross-Sectional Study in 190-Graft Recipients Up to 20 Years After Transplantation,” Transplantation, 1995, 59(7):982-6. [PubMed 7709459]
  48. Gutin PH, “Corticosteroid Therapy in Patients With Brain Tumors,” Natl Cancer Inst Monogr, 1977, 46:151-6. [PubMed 349394]
  49. Hahn BH, McMahon MA, Wilkinson A, et al, "American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis," Arthritis Care Res (Hoboken), 2012, 64(6):797-808. [PubMed 22556106]
  50. Hengstman GJ, van den Hoogen FH, and van Engelen BG, “Treatment of the Inflammatory Myopathies: Update and Practical Recommendations,” Expert Opin Pharmacother, 2009, 10(7):1183-90. [PubMed 19405792]
  51. Hiratzka LF, Bakris GL, Beckman JA, et al, “2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine,” J Am Coll Cardiol, 2010, 55(14):e27-129. [PubMed 20359588]
  52. Hogg RJ, Portman RJ, Milliner D, et al, “Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),” Pediatrics, 2000, 105(6):1242-9. [PubMed 10835064]
  53. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  54. Iorizzo LJ 3rd and Jorizzo JL, “The Treatment and Prognosis of Dermatomyositis: An Updated Review,” J Am Acad Dermatol, 2008, 59(1):99-112. [PubMed 18423790]
  55. Ismael H, Horst M, Farooq M, Jordon J, Patton JH, Rubinfeld IS. Adverse effects of preoperative steroid use on surgical outcomes. Am J Surg. 2011; 201(3):305-308. [PubMed 21367368]
  56. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al, "Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study," JAMA Intern Med, 2013, 1:1-10. [PubMed 23546607]
  57. Jusko WJ and Rose JQ, “Monitoring Prednisone and Prednisolone,” Ther Drug Monit, 1980, 2(2):169-76. [PubMed 6762710]
  58. Katz FH and Duncan BR, "Letter: Entry of Prednisone Into Human Milk," N Engl J Med, 1975, 293(22):1154. [PubMed 1186783]
  59. KDIGO. Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements. June 2012.
  60. KDIGO. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2013;62(3):403-441. [PubMed 23871408]
  61. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-1461. [PubMed 23024029]
  62. Kimberly RP, “Glucocorticoids,” Curr Opin Rheumatol, 1994, 6(3):273-80. [PubMed 8060761]
  63. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68(19):1607-1613. [PubMed 17485648]
  64. Kornbluth A and Sachar DB, “Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,” Am J Gastroenterol, 2010, 105(3):501-23. [PubMed 20068560]
  65. Leachman SA and Reed BR, "The Use of Dermatologic Drugs in Pregnancy and Lactation," Dermatol Clin, 2006, 24(2):167-97, vi. [PubMed 16677965]
  66. Lichtenstein GR, Hanauer SB, and Sandborn WJ, “Management of Crohn's Disease in Adults,” Am J Gastroenterol, 2009, 104(2):465-83. [PubMed 19174807]
  67. Lieberman P, Kemp SF, Oppenheimer J, et al, “The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter,” J Allergy Clin Immunol, 2005, 115(3 Suppl 2):483-523. [PubMed 15753926]
  68. Lougheed MD, Lemière C, Dell SD, et al, “Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,” Can Respir J, 2010, 17(1):15-24. [PubMed 20186367]
  69. Lowenthal RM and Jestrimski KW, “Corticosteroid Drugs: Their Role in Oncological Practice,” Med J Aust, 1986, 144(2):81-5. [PubMed 2417096]
  70. Lunghi L, Pavan B, Biondi C, et al, "Use of Glucocorticoids in Pregnancy," Curr Pharm Des, 2010, 16(32):3616-37. [PubMed 20977425]
  71. Maisch B, Seferovic PM, Ristic AD, et al. Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2004;25(7):587-610. [PubMed 15120056]
  72. Makol A, Wright K, and Amin S, "Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management," Drugs, 2011, 71(15):1973-87. [PubMed 21985166]
  73. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-2213. [PubMed 20513004]
  74. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18(5):365-370. doi: 10.1016/j.nmd.2008.03.002. [PubMed 18436445]
  75. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. [PubMed 27149418]
  76. McGee S and Hirschmann J, “Use of Corticosteroids in Treating Infectious Diseases,” Arch Intern Med, 2008, 168(10):1034-46. [PubMed 18504331]
  77. Moxley RT 3rd, Ashwal S, Pandya S, et al, “Practice Parameter: Corticosteroid Treatment of Duchenne Dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,” Neurology, 2005, 64(1):13-20. [PubMed 15642897]
  78. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401. [PubMed 24528911]
  79. Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. J Investig Allergol Clin Immunol. 2016;26(1):1-7. [PubMed 27012010]
  80. National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3, "Guidelines for the Diagnosis and Management of Asthma," Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
  81. National Asthma Education and Prevention Program (NAEPP) Working Group Report on “Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,” National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf
  82. National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. Published October 8, 2014. Available at http://www.nice.org.uk/guidance/cg186.
  83. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. doi: 10.1182/blood-2010-08-302984. [PubMed 21325604]
  84. Østensen M and Forger F, "Management of RA Medications in Pregnant Patients," Nat Rev Rheumatol, 2009, 5(7):382-90. [PubMed 19506586]
  85. Ost L, Wettrell G, Bjorkhem I, et al, "Prednisolone Excretion in Human Milk," J Pediatr, 1985, 106(6):1008-11. [PubMed 3998938]
  86. Park-Wyllie L, Mazzotta P, Pastuszak A, et al, “Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-analysis of Epidemiological Studies,” Teratology, 2000, 62(6):385-92. [PubMed 11091360]
  87. Pradat P, Robert-Gnansia E, Di Tanna GL, et al, “First Trimester Exposure to Corticosteroids and Oral Clefts,” Birth Defects Res A Clin Mol Teratol, 2003, 67(12):968-70. [PubMed 14745915]
  88. Prednisone tablet, solution, solution concentrate [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.
  89. Rayos (prednisone) [prescribing information]. Lake Forest, IL; Horizon Pharma USA, Inc; July 2016.
  90. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, “Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,” Arch Dis Child, 1994, 70(2):151-7. [PubMed 8129444]
  91. Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J South Afr. 2006;17(5):233-238. [PubMed 17117227]
  92. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. [PubMed 27457514]
  93. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi 10.1089/thy.2016.0229. [PubMed 27521067]
  94. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-160. [PubMed 25601341]
  95. Sagraves R, Kaiser D, and Sharpe GL, “Prednisone and Prednisolone Concentrations in the Milk of a Lactating Mother,” Drug Intell Clin Pharm, 1981, 15:484.
  96. Salem M, Tainsh RE Jr, Bromberg J, et al, “Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,” Ann Surg, 1994, 219(4):416-25. [PubMed 8161268]
  97. Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 2013;61:948–954. [PubMed 23352781]
  98. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG; Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128-2134. [PubMed 22156988]
  99. Sivera F, Andrés M, Carmona L, et al. Multinational Evidence-Based Recommendations for the Diagnosis and Management of Gout: Integrating Systematic Literature Review and Expert Opinion of a Broad Panel of Rheumatologists in the 3e Initiative. Ann Rheum Dis. 2014;73(2):328-335. [PubMed 23868909]
  100. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512. [PubMed 15470213]
  101. US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated September 24, 2015. Accessed September 25, 2015.
  102. van Runnard Heimel PJ, Schobben AF, Huisjes AJ, et al, “The Transplacental Passage of Prednisolone in Pregnancies Complicated by Early-Onset HELLP Syndrome,” Placenta, 2005, 26(10):842-5. [PubMed 16226134]
  103. Verbeek PR and Geerts WH, “Nontapering Versus Tapering Prednisone in Acute Exacerbations of Asthma: A Pilot Trial,” J Emerg Med, 1995, 13(5):715-9. [PubMed 8530798]
  104. Wallace DV, Dykewicz MS, Bernstein DI, et al, “The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter,” J Allergy Clin Immunol, 2005, 115(3 Suppl 2):483-523. [PubMed 18662584]
  105. Wiendl H, “Idiopathic Inflammatory Myopathies: Current and Future Therapeutic Options,” Neurotherapeutics, 2008, 5(4):548-57. [PubMed 19019306]
  106. Wolkowitz OM, “Long-Lasting Behavioral Changes Following Prednisone Withdrawal,” JAMA, 1989, 261(12):1731-2. [PubMed 2918667]
  107. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
  108. Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
  109. Zhang W, Doherty M, Bardin T, et al. EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. [PubMed 16707532]
Topic 9809 Version 269.0